Sponsors / TARA
TARA

Protara Therapeutics

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
4Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of AgeNCT05871970Protara TherapeuticsPhase 2Recruiting2026-12Estimated
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder CancerNCT05951179Protara TherapeuticsPhase 2Recruiting2031-10Estimated
Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral SupportNCT06910943Protara TherapeuticsPhase 2, Phase 3Recruiting2028-03Estimated
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerNCT07480356Protara TherapeuticsPhase 3Recruiting2028-04Estimated

Latest recorded trial changes

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

NCT05951179 · Protara Therapeutics

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002 Measure: Cohort A: Incidence of high-grade Complete Response at any time by subgroup (BCG naive and BCG exposed > 24 months) according to central pathology after treatment with TARA-002

+ After

Measure: Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002

Primary completion date changed

− Before

May 2030

+ After

Oct 2031

Check registry source